Latest Active Biotech News & Updates

See the latest news and media coverage for Active Biotech. We track all announcements, press releases, and industry mentions in real time, all in one place.

Active Biotech

Biotechnology company developing treatments for cancer and inflammatory eye diseases

activebiotech.com

Headquarters: Lund, Sweden
Founded year: 1998
Company type: Public company
Number of employees: 10–19
Industry: Pharmaceuticals

Last updated October 13

Latest news about Active Biotech

In short: Active Biotech completed tasquinimod safety cohort, secured Japan laquinimod patent, expanded US collaboration, and reported Q2 loss.

Company announcements

October 13 Active Biotech

Active Biotech completes safety evaluation in tasquinimod study

The first cohort finished the assessment, confirming tolerability for the revised regimen, and recruitment continues with three more patients.

September 30 Active Biotech

Active Biotech receives Japan patent for laquinimod ophthalmic formulation

Japan Patent Office granted patent covering laquinimod formulation for severe inflammatory eye diseases like non-infectious uveitis.

August 18 Active Biotech

Active Biotech expands collaboration in the US with Mount Sinai

The collaboration aims to accelerate clinical development of tasquinimod for myelofibrosis. A preclinical program is launched to validate the drug's effect.

July 24 Active Biotech

Active Biotech announced first patient dosed in amended HO172 study

The Phase Ib/II study evaluates tasquinimod in myelofibrosis patients refractory to JAK2 inhibitors, with greater dosing flexibility.

Media coverage

August 20 RTTNews

Active Biotech's Q2 Loss Shrinks As Dosing Begins In Myelofibrosis Trial

Active Biotech AB (publ) (ACTI.ST), an immunomodulatory treatment company, on Thursday announced interim financial results for the second quarter and registered a marginally lower loss...

July 23 Finanznachrichten

Active Biotech AB: First patient dosed in the amended HO172 clinical study of tasquinimod in myelofibrosis

Lund Sweden, July 24, 2026 - Active Biotech (NASDAQ STOCKHOLM: ACTI) today announced that the first patient has been dosed in the Phase Ib/II clinical...

May 28 Finanznachrichten

Active Biotech AB: Active Biotech announces timetable for reverse share split

The Annual General Meeting in Active Biotech AB (publ) ("Active Biotech" or the "Company") held on May 20, 2026, resolved to carry out a reverse...

May 19 Salisbury Post

Unaudited Preliminary Results for the Year Ended December 31, 2025

LONDON and PHILADELPHIA, May 19, 2026 (GLOBE NEWSWIRE) -- Avacta Therapeutics (AIM: AVCT, “the Company”, “Avacta”), a clinical stage biopharmaceutical company developing pre|CISION, a tumor-activated...

Never miss news about Active Biotech

Track Active Biotech and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

Active Biotech competitors & trending companies

Browse news for competitors to Active Biotech and other trending companies.